Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05445232 · ClinicalTrials.gov registry record · Phase 1

A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

A Phase 1 study of Obesity, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
2
Study locations

NCT05445232 is a Phase 1 study of Obesity that has completed, run by Eli Lilly and Company. The registered enrollment target is 32 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05445232, a Phase 1 study of Obesity, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
2
Study locations

Study Summary

The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each participant.

Conditions Studied

Obesity

Interventions

  • DRUG Midazolam
  • DRUG Caffeine
  • DRUG Warfarin
  • DRUG LY3437943

Study Locations (2)

Florida

  • Covance Clinical Research Unit - Daytona Beach

Texas

  • Covance Dallas - Dallas

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2022-07-08
Est. Completion 2023-02-24
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05445232

The ClinicalTrials.gov registry entry for NCT05445232 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Midazolam is the first listed.

NCT05445232 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT05445232 about?

NCT05445232 is a clinical study titled "A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants". The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each ...

What is the current status of trial NCT05445232?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-07-08. Estimated completion is 2023-02-24.

What conditions does trial NCT05445232 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT05445232?

The interventions under investigation include: Midazolam (DRUG), Caffeine (DRUG), Warfarin (DRUG), LY3437943 (DRUG).

Who is sponsoring clinical trial NCT05445232?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05445232 being conducted?

This trial has 2 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.